Use and misuse of opioid replacement therapies: A queensland study

Substance Use and Misuse

Volumn 47, Issue 1, 2012, Pages 78-85

  Smirnov, Andrew ^a,b   Kemp, Robert ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QUEENSLAND HEALTH   (Australia)

Author keywords

Australia; Buprenorphine; Buprenorphine naloxone; Diversion liability; Harm minimization; Harm reduction; Methadone; Misuse; Needle syringe program; Unsupervised dosing

Indexed keywords

BUPRENORPHINE; METHADONE; NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ADDICTION; ARTICLE; AUSTRALIA; DRUG COMBINATION; DRUG EFFECT; HARM REDUCTION; HUMAN; METHODOLOGY; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; RETROSPECTIVE STUDY; SUBSTANCE ABUSE;

ANALGESICS, OPIOID; BUPRENORPHINE; DRUG COMBINATIONS; HARM REDUCTION; HUMANS; METHADONE; NALOXONE; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; QUEENSLAND; RETROSPECTIVE STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS;

EID: 84855491613     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.3109/10826084.2011.629017     Document Type: Article

References (26)

1. Alho, H., Sinclair, D., Vuori, E., & Holopainen, A.2007). Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug and Alcohol Dependence, 88, 75-78. (Pubitemid 46400304)
2. Auriacombe, M., Fatséas, M., Dubernet, J., Dauloùede, J., & Tignol, J.2004). French field experience with buprenorphine. The American Journal on Addictions / American Academy of Psychiatrists in Alcoholism and Addictions, 13(Suppl. 1), S17-S28. (Pubitemid 38585688)
3. Auriacombe, M., Franques, P., & Tignol, J.2001). Deaths attributable to methadone vs buprenorphine in France. JAMA: The Journal of the American Medical Association, 285(1), 45. (Pubitemid 32042714)
4. Bell, J. R., Butler, B., Lawrance, A., Batey, R., & Salmelainen, P.2009). Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug and Alcohol Dependence, 104(1-2), 73-77.
5. Boeuf, O., & Lapeyre-Mestre, M.2007). Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: Results of OSIAP survey. Drug Safety: An International Journal of Medical Toxicology and Drug Experience, 30(3), 265-276. (Pubitemid 46425637)
6. Chawarski, M. C., Schottenfeld, R. S., O'Connor, P. G., & Pakes, J.1999). Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Drug and Alcohol Dependence, 55(1-2), 157-163. (Pubitemid 29222014)
7. Comer, S. D., & Collins, E. D.2002). Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. The Journal of Pharmacology and Experimental Therapeutics, 303(2), 695-703. (Pubitemid 35231243)
8. Degenhardt, L., Larance, B. K., Bell, J. R., Winstock, A. R., Lintzeris, N., Ali, R. L., et al.2009). Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. The Medical Journal of Australia, 191(3), 161-165.
9. Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., et al.2003). Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. The New England Journal of Medicine, 349(10), 949-958. (Pubitemid 37064768)
10. Fudala, P. J., Yu, E., Macfadden, W., Boardman, C., & Chiang, C. N.1998). Effects of buprenorphine and naloxone in morphinestabilized opioid addicts. Drug and Alcohol Dependence, 50(1), 1-8. (Pubitemid 28176605)
11. Johansen, S. S, Jacobsen, C., Müller, I. B., Petersen, H.W., Simonsen, K.W., Kringsholm, B., et al.2006). [Fatal cases of poisoning in eastern Denmark during a five-year period (1998-2002)]. Ugeskrift for Laeger, 168(39), 3326-3331. (Pubitemid 44482414)
12. Kakko, J., Grönbladh, L., Svanborg, K. D., von Wachenfeldt, J., Rück, C., Rawlings, B., et al.2007). A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: A randomized controlled trial. The American Journal of Psychiatry, 164(5), 797-803. (Pubitemid 46808535)
13. Kintz, P.2001). Deaths involving buprenorphine: A compendium of French cases. Forensic Science International, 121(1-2), 65-69. (Pubitemid 32758815)
14. Kintz, P.2002a). Buprenorphine-related deaths deaths. In: P. Kintz & P.Marquet (Eds.), Buprenorphine therapy of opiate addiction (pp. 109-118). Totowa, NJ: Humana Press.
15. Kintz, P.2002b). A new series of 13 buprenorphine-related deaths. Clinical Biochemistry, 35(7), 513-516. (Pubitemid 35462125)
16. Lewis, J. W.1985). Buprenorphine. Drug and Alcohol Dependence, 14(3-4), 363-372. (Pubitemid 15149057)
17. Lintzeris, N., Mitchell, T. B., Bond, A. J., Nestor, L., & Strang, J.2007). Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients. Drug and Alcohol Dependence, 91(2-3), 187-194. (Pubitemid 47554601)
18. Mendelson, J., & Jones, R. T.2003). Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: Why the 4:1 ratio for treatment? Drug and Alcohol Dependence, 70(2 Suppl.), S29-S37. (Pubitemid 36556058)
19. Mendelson, J., Jones, R. T., Fernandez, I., Welm, S., Melby, A. K., & Baggott, M. J.1996). Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clinical Pharmacology and Therapeutics, 60(1), 105-114. (Pubitemid 26279227)
20. Mendelson, J., Jones, R.T., Welm, S., Baggott, M., Fernandez, I., Melby, A.K., et al.1999). Buprenorphine and naloxone combinations: The effects of three dose ratios in morphinestabilized, opiate-dependent volunteers. Psychopharmacology, 141(1), 37-46. (Pubitemid 29193293)
21. Nielsen, S., Dietze, P., Lee, N., Dunlop, A., & Taylor, D.2007). Concurrent buprenorphine and benzodiazepines use and selfreported opioid toxicity in opioid substitution treatment. Addiction (Abingdon, England), 102(4), 616-622. (Pubitemid 46398829)
22. Queensland Needle and Syringe Program.2009). Needle and syringe program policy. Brisbane: Queensland Needle and Syringe Program, Queensland Health.
23. Tracqui, A., Tournoud, C., Flesch, F., Kopferschmitt, J., Kintz, P., Deveaux, M., et al.1998). [Acute poisoning during substitution therapy based on high-dosage buprenorphine. 29 clinical cases: 20 fatal cases]. Presse Médicale (Paris, France: 1983), 27(12), 557-561. (Pubitemid 28164266)
24. Treloar, C., & Cao, W.2005). Barriers to use of needle and syringe programmes in a high drug use area of Sydney, New South Wales. International Journal of Drug Policy, 16(5), 308-315. (Pubitemid 41399678)
25. Walsh, S. L., Preston, K. L., Bigelow, G. E., & Stitzer, M. L.1995). Acute administration of buprenorphine in humans: Partial agonist and blockade effects. The Journal of Pharmacology and Experimental Therapeutics, 274(1), 361-372.
26. Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E.1994). Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology and Therapeutics, 55(5), 569-580. (Pubitemid 24192243)